Eco Animal Health Group diversifying its product portfolio
July 27, 2023 at 08:25 am EDT
Share
(via NewsDirect)
ECO Animal Health Group PLC (AIM: EAH) CEO David Hallas speaks to Thomas Warner from Proactive about the company's recent performance and his hopes for its future, during his first interview on the platform. Hallas starts by giving an overview of the business, which specialises in developing, registering and marketing pharmaceutical products for global animal health markets and particularly for pigs and chickens.
The company's flagship product Aivlosin is a proprietary, patented medication which is effective against both respiratory and enteric diseases in pigs and poultry is an anti-infective treatment for respiratory and enteric diseases in animals. Over the past year, the company achieved 4% revenue growth, surpassing market expectations. Hallas highlighted strong growth in Latin America and South and Southeast Asia, driven by increasing demand for high-quality white meat.
Looking ahead, Eco Animal Health plans to diversify into preventative disease solutions, such as vaccines and monoclonal antibodies, targeting the US market by the end of next year. Hallas also addressed misconceptions, emphasising that the company's growth is not solely reliant on the Chinese market and that a balanced approach of prevention and treatment is essential for success.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
ECO Animal Health Group plc is a United Kingdom-based animal health biotechnology company. The Company is engaged in the manufacturing and supplying of animal health products globally. The Company is focused on providing solutions to respiratory and enteric diseases in pigs and poultry. It provides quality products for swine and poultry, primarily anti-infectives. The Companyâs segment includes the United Kingdom, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World. The Company research, develops and commercializes products for livestock. The Companyâs lead product, Aivlosin, is an antimicrobial which is used under veterinary prescription for the treatment of economically important respiratory and gastrointestinal diseases in pigs and poultry. The Company is also engaged in researching and developing new solutions to enhance the lives of pigs and poultry.